Skipping the Advisory Committee, but Getting the Advice
This article was originally published in RPM Report
Executive Summary
Pfizer’s Xalkori sailed through FDA without an advisory committee review. But FDA did consult with two outside advisors--including the Oncology Committee Chair--along the way.